This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
After a blockbuster start to the year, gold lost its luster plunging to one-year low thanks to a strengthening dollar and interest rate hikes. The yellow metal is down 10% from its January high, which confirms that the gold market has slipped into correction territory. Below, we have discussed various factors that have influenced the price of the gold and will continue to do so: Strong Dollar & Rate Hike The U.
NDMWF PVG ELD NAK CMCL PVG CMCL EGO
A news article last week explained that Rio Tinto is actively seeking to acquire a big copper project, as it aims to diversify its metal production.
NSU NDMWF RTPPF RIO RIO RIO NAK RTNTF FQVLF NGQRF FQM NGQ
Chicago, IL – June 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include National Bank Holdings Corporation (NBHC - Free Report) , Blue Hills Bancorp, Inc. (BHBK - Free Report) , Loews Corporation (L - Free Report) , LPL Financial Holdings Inc.
LPLA HD NBHC ELY ACCO BHBK LXFR WTW L GIII MAR.WI MAR NDMWF DK NAK ENBL URBN HLT KOS AAXN
The likelihood of an interest rate hike by the Federal Reserve at the conclusion of its June 12-13 FOMC meeting is pretty high. The Fed funds rate is expected to tick up 25 basis points, with another hike or two anticipated this year. The possibility is backed by low unemployment, wage growth and rise in headline inflation.
LPLA HD NDMWF NBHC BHBK AAPL NAK TRI L
Northern Dynasty Minerals Ltd. (NAK - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors, there is some hope when looking at NAK given that, according to its RSI reading of 25.15, it is now in oversold territory.
MGM NDMWF ABRN ABR ABRN.CL NAK ABR.PRB ABR.PRC ABR.PRA
Shares of Deutsche Bank AG fell 2.8% on Thursday as critics demanded the resignation of Chairman Paul Achleitner at the bank's annual general meeting. Journalists present at the Frankfurt meeting reported that critics piled in and proposed that the chairman should be removed. The critical shareholders accused Achleitner of being involved in criminal activities, such as fraud, according to Tweets from journalists at the event.
STAN C.WSA DB BNPQY PCBB CBQS FITBI C.WS.B SCGLF STAB C.WS.A STAC SCBFF STAN NAK C.PRP C.PRU 3772 C.PRS C C.PRL C.PRJ C.PRK 55BC SCGLY BNPQF C.PRG C.PRC NDMWF BNPZY C.PRPCL CGBBW 580001 2888 FITB GLE
* NORTHERN DYNASTY MINERALS LTD - AGREED TO EXTEND DEADLINE DATE OF FRAMEWORK AGREEMENT WITH FIRST QUANTUM MINERALS TO APRIL 30, 2018 Source text for Eikon: Further company coverage:
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET